SAN RAFAEL, Calif. – Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), a recognized trailblazer in the field of exoskeleton technology for both medical and industrial applications, today announced its comprehensive financial results for the second quarter and first half of the fiscal year, concluded on June 30, 2025. This period, while presenting certain challenges, also marked significant strides in the Company’s strategic initiatives and product development.
Recent Highlights and Accomplishments Drive Future Growth
Ekso Bionics demonstrated its ongoing commitment to innovation and market expansion through several key achievements during the second quarter:
- Strategic Distribution Partnership: The Company proudly announced Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its inaugural Ekso Indego Personal device distributor within the crucial orthotics and prosthetics industry. This collaboration is set to significantly broaden the reach and accessibility of Ekso Bionics’ personal mobility solutions.
- Pioneering AI Integration: Ekso Bionics was formally accepted into the prestigious NVIDIA Connect program. This pivotal inclusion underpins Ekso’s ambitious new strategic initiative: to construct a proprietary foundation model for human motion. This advanced model will serve as the bedrock for developing and seamlessly integrating cutting-edge artificial intelligence (“AI”) capabilities across the Company’s entire portfolio of Enterprise Health and Personal Health devices, promising enhanced functionality and user experience.
- Rapid Proof-of-Concept for AI Voice Agent: Demonstrating exceptional agility, just over a month after its acceptance into the NVIDIA Connect program, Ekso Bionics unveiled its initial proof-of-concept in the form of a new AI voice agent, aptly named ‘Ekso Voice Agent’. This innovative agent is specifically designed for intelligent control of the Company’s legacy EksoNR device, offering a glimpse into the future of intuitive human-exoskeleton interaction.
- Empowering Clinical Professionals: The Company successfully launched eksoUniversity, a novel educational platform. This valuable resource provides a rich library of continuing education courses specifically tailored for physical therapists and physical therapy assistants. The platform aims to empower these crucial healthcare professionals with the latest knowledge and skills required to effectively work with patients suffering from neurological conditions, further solidifying Ekso Bionics’ commitment to patient care and professional development.
Scott Davis, the Company’s Chief Executive Officer, provided insights into the quarter’s performance and the forward-looking strategy. He commented, “While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device Enterprise Health sales, we are working to get back on track for the second half of the year and beyond. In addition to pulling in those aforementioned sales deferrals and continuing to meet anticipated Enterprise Health customer demand, we expect that to be bolstered by an increasing contribution from our Personal Health products, which grew by more than 50% year-over-year in the first half of 2025.”
Summary of Second Quarter 2025 Financial Results
For the quarter ended June 30, 2025, Ekso Bionics recorded revenue of $2.1 million, compared to $5.0 million for the corresponding period in 2024. This change was primarily attributed to lower sales of Enterprise Health devices, though partially offset by robust growth in Ekso Indego Personal device sales.
Gross profit for the 2025 second quarter stood at $0.8 million, translating to a gross margin of approximately 40%. This compares to $2.6 million for the same period in 2024, which represented a gross margin of 53%. The variance in gross profit was driven by a decrease in revenues associated with Enterprise Health devices, mitigated by increased revenues from Ekso Indego Personal devices and a reduction in service costs. The decline in gross margin was primarily influenced by fixed costs of goods relative to the decrease in Enterprise Health device sales, lower margin sales due to increased distribution volume, and a rise in shipping costs. These factors were partially offset by improved margins within the service segment.
Sales and marketing expenses for the 2025 second quarter were $1.7 million, a slight decrease from $1.8 million for the same period in 2024. This reduction was primarily due to lower discretionary payroll expense.
Research and development expenses for the three months ended June 30, 2025, amounted to $0.9 million, compared to $1.1 million for the identical period in 2024. The change was predominantly a result of lower headcount.
General and administrative expenses for the 2025 second quarter were $2.3 million, an increase from $2.0 million for the same period in 2024. This rise was primarily attributable to lower allocable costs to manufacturing.
The net loss applicable to common stockholders for the 2025 second quarter was $2.7 million, or $1.24 per basic and diluted share. This compares to a net loss of $2.4 million, or $1.99 per basic and diluted share, for the corresponding period in 2024.
As of June 30, 2025, the Company maintained a healthy liquidity position with cash and restricted cash totaling $5.2 million.
Advancing Human Potential: Insights into Exoskeleton Technology
- The global exoskeleton market is projected to grow significantly, driven by increasing applications in rehabilitation, industrial safety, and defense.
- Exoskeletons offer life-changing mobility for individuals with spinal cord injuries and other neurological conditions, vastly improving their independence and quality of life.
- Beyond medical applications, industrial exoskeletons are gaining traction for reducing worker fatigue and injuries in demanding physical jobs, leading to increased productivity and safety.
- The integration of artificial intelligence (AI) is rapidly enhancing exoskeleton capabilities, allowing for more intuitive control, personalized assistance, and advanced data analysis for improved patient outcomes and operational efficiency.
Conference Call Details
Ekso Bionics extends an invitation to all interested parties to participate in a conference call today, beginning at 1:30 p.m. PT / 4:30 p.m. ET. During this call, the Company’s financial results and recent business developments will be discussed in detail.
To participate by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). A live broadcast of the call will also be available, along with an archived recording, on the Company’s website at www.eksobionics.com, accessible through the “Presentations & Events” section under “Investors.”
About Ekso Bionics
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]
